THEY WILL RUIN YOUR COMPUTER.
I'm posting the scam alert on every board i see ultimate stock alerts mentioned.
DON'T GO TO THAT SITE!
Form 8-K for SUNEDISON, INC.
Item 8.01 Other Events.
On August 28, 2015, Mr. Ahmad Chatila, President and Chief Executive Officer of SunEdison, Inc. (the "Company"), purchased 9,700 shares of the Company's common stock on the open market. Mr. Chatila holds outright over 300,000 shares of SunEdison, the majority of which he used personal funds to purchase. As filed earlier today on Form 4, Statement of Changes in Beneficial Ownership for the Company, Mr. Chatila beneficially owns 845,672 shares of the Company.
all the institutional holders are serious players and most have lost their butts on this one
Brokerages Expect OHR Pharmaceutical to Announce ($0.24) EPS (NASDAQ:OHRP)
August 31st, 2015 - 0 comments - Filed Under - by Samantha Reynolds
Share on StockTwits
OHR Pharmaceutical logoShares of OHR Pharmaceutical (NASDAQ:OHRP) have been given a consensus broker rating score of 1.50 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and three have issued a strong buy rating on the company.
Brokers have set a 1-year consensus target price of $30.00 for the company and are predicting that the company will post ($0.24) earnings per share for the current quarter, according to Zacks. Zacks has also given OHR Pharmaceutical an industry rank of 89 out of 265 based on the ratings given to its competitors.
Shares of OHR Pharmaceutical (NASDAQ:OHRP) opened at 2.85 on Monday. OHR Pharmaceutical has a 52 week low of $2.02 and a 52 week high of $12.31. The firm’s market cap is $86.44 million. The stock has a 50 day moving average of $2.91 and a 200-day moving average of $4.15.
A number of research firms have issued reports on OHRP. Zacks upgraded shares of OHR Pharmaceutical from a “hold” rating to a “strong-buy” rating and set a $3.00 target price on the stock in a research note on Tuesday, August 18th. Brean Capital restated a “buy” rating and issued a $30.00 price target (down from $34.00) on shares of OHR Pharmaceutical in a research report on Friday, August 7th. Roth Capital reiterated a “buy” rating and set a $30.00 target price on shares of OHR Pharmaceutical in a research report on Monday, July 13th. Finally, Chardan Capital reissued a “hold” rating on shares of OHR Pharmaceutical in a report on Sunday, May 10th.
price targets $30+ with three out of four analysts giving strong buys!!!
See insider transactions tab. They see the long-term potential. That's why the average price target right now is $19.
According to Smarter Analyst, Brean Capital, LLC analyst Jonathan Aschoff weighed in on OHR Pharmaceutical following the positive results, giving the stock a Buy rating with a share target price of $34. Though the analyst believes “It will be more informative to see results from a much larger placebo controlled, multi-site trial where squalamine is given only to one trial arm for the entire duration,” he still thinks “this initial squalamine trial still compares favorably, and supports further development.” Aschoff is also looking forward to “[OHR] clarifying the design for its pivotal wet AMD trials, as well as next steps for squalamine in retinal vein occlusion.”
Aschoff explained his valuation on the stock, noting, “We derive our target price of $34 through a DCF analysis, assuming a 30% discount rate that is applied to all cash flows and the terminal value, which is based on a 4 multiple of the projected 2019 earnings before interest, taxes, depreciation, and amortization.”
Similarly, Roth Capital Partners analyst Elemer Piros reiterated a Buy rating on OHR Pharmaceutical with a share target price of $30. The analyst valued the company’s “price target of $30/share based on an NPV analysis for OHR-102 in AMD in the U.S. alone.” Piros estimates “that OHR-102 may reach ~$1.3B in U.S. annual sales by 2023,” assuming the drug launches in 2019. The analyst cites a few factors that may prevent OHRP from reaching $30 a share, including a “delay in patient enrollment and data announcement, poor trial outcome and adverse market conditions for stocks in the biotechnology sector.”
Out of three analysts polled by TipRanks over the past three months, two analysts are bullish on OHR Pharmaceuticals and one is neutral. The average 12-month price target of the stock is $18.50, marking an overwhelming 401.36% potential upside from where shares are currently trading. On average, the all-analyst consensus for OHRP on TipRanks is Moderate Buy.
Cash is twice the market cap with limited debt?
It could happen with KBIO. Never underestimate momentum traders